FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileScilex Holding Company
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SCLXW
Scilex Holding Company Stock AnalysisComprehensive stock analysis for Scilex Holding Company (SCLXW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSCLXW
SCLXW
Scilex Holding Company
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SCLXW
  1. Home
  2. Stocks
  3. Scilex Holding Company

Scilex Holding Company

🇺🇸SCLXW•NASDAQ

Scilex Holding Company

🇺🇸SCLXW•NASDAQ
Market cap
$14.07M

Your view on SCLXW

Mkt Cap
$14.07M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Scilex Holding Company

Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Henry H. Ji
Headquarters
960 San Antonio Road, Palo Alto, CA, US
Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Henry H. Ji
Headquarters
960 San Antonio Road, Palo Alto, CA, US
Description

Scilex Holding Company operates as a biopharmaceutical firm primarily engaged in creating and distributing non-opioid treatments for individuals suffering from acute and chronic pain conditions. Its flagship product, ZTlido 1.

8%, is a prescription-only topical lidocaine formulation designed to alleviate neuropathic pain, specifically that associated with post-herpetic neuralgia, a type of nerve pain occurring after a shingles infection.

The company's development pipeline also features SP-102, known as SEMDEXA, a viscous corticosteroid gel administered via epidural injections. This candidate is currently in Phase 3 clinical trials, targeting lumbosacral radicular pain.

Another investigational drug, SP-103, aims to treat low back pain and is progressing through Phase 2 clinical trials. Additionally, SP-104, an innovative low-dose, delayed-release naltrexone hydrochloride formulation, is in Phase 1 clinical development for managing fibromyalgia.

Scilex Holding Company is headquartered in Palo Alto, California, and functions as a subsidiary of Sorrento Therapeutics, Inc.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Scilex Holding Company. Starting points for Scilex Holding Company: EPS -$64.87, beta 1.74 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Scilex Holding Company. Trailing twelve-month EPS for Scilex Holding Company stands at -$64.87. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Scilex Holding Company. Scilex Holding Company has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold SCLXW12 companies
More Drug Manufacturers - General companies
TickerTypeCompanySectorExchangeMkt cap
GIFOFGrifols, S.A.HealthcareOTC$8.7B
GIKLYGrifols, S.A.HealthcareOTC$17.0B
GILDGilead Sciences, Inc.HealthcareNASDAQ$206.4B
GLAXFGSK plcHealthcareOTC$118.6B
GRFSGrifols, S.A.HealthcareNASDAQ$6.9B
GSKGSK plcHealthcareNYSE$96.3B
HAWPFHaw Par Corporation LimitedHealthcareOTC$3.1B
HAWPYHaw Par Corporation LimitedHealthcareOTC$3.0B
JCRRFJCR Pharmaceuticals Co., Ltd.HealthcareOTC$508.7M
JNJJohnson & JohnsonHealthcareNYSE$651.1B
LLYEli Lilly and CompanyHealthcareNYSE$1.3T
LLY.TOEli Lilly and CompanyHealthcareTSX$1.7T
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Scilex Holding Company executives and directors. Shares of Scilex Holding Company have traded between $0.17 and $0.21 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Scilex Holding Company. Coverage tracks Scilex Holding Company within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Scilex Holding Company.

SCLXW AnalysisWeak
Past
1
Growth
1
Health
1
Profit
1
Value
1